Clinical Outcomes of Acute Myocardial Infarction Patients With a History of Malignant Tumor.


Journal

In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809

Informations de publication

Date de publication:
Historique:
received: 12 09 2020
revised: 24 09 2020
accepted: 25 09 2020
entrez: 4 11 2020
pubmed: 5 11 2020
medline: 22 6 2021
Statut: ppublish

Résumé

Little is known about the clinical outcomes of acute myocardial infarction (AMI) in patients with a history of malignant tumor (MT). We retrospectively studied 1,295 consecutive patients with AMI who underwent primary percutaneous coronary intervention within 24 hours of onset. The patients were divided into two groups: those with a history of MT (MT group, n=50) and those without (non-MT group, n=1,245). The MT group was older, and had lower hemoglobin, total protein, and albumin levels. All-cause mortality and re-admission rates due to acute decompensated heart failure (ADHF) were significantly higher in the MT group. Multivariate analysis showed that a history of MT was an independent predictor for all-cause mortality and re-admission due to ADHF. The clinical outcomes of patients with AMI with a history of MT are poor, and a history of MT is an independent predictor for all-cause mortality and re-admission due to ADHF. These patients may need careful risk management for heart failure to avoid re-admissions due to ADHF.

Sections du résumé

BACKGROUND BACKGROUND
Little is known about the clinical outcomes of acute myocardial infarction (AMI) in patients with a history of malignant tumor (MT).
PATIENTS AND METHODS METHODS
We retrospectively studied 1,295 consecutive patients with AMI who underwent primary percutaneous coronary intervention within 24 hours of onset. The patients were divided into two groups: those with a history of MT (MT group, n=50) and those without (non-MT group, n=1,245).
RESULTS RESULTS
The MT group was older, and had lower hemoglobin, total protein, and albumin levels. All-cause mortality and re-admission rates due to acute decompensated heart failure (ADHF) were significantly higher in the MT group. Multivariate analysis showed that a history of MT was an independent predictor for all-cause mortality and re-admission due to ADHF.
CONCLUSION CONCLUSIONS
The clinical outcomes of patients with AMI with a history of MT are poor, and a history of MT is an independent predictor for all-cause mortality and re-admission due to ADHF. These patients may need careful risk management for heart failure to avoid re-admissions due to ADHF.

Identifiants

pubmed: 33144472
pii: 34/6/3589
doi: 10.21873/invivo.12203
pmc: PMC7811638
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3589-3595

Informations de copyright

Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Références

J Am Coll Cardiol. 2004 Sep 1;44(5):959-66
pubmed: 15337204
J Am Coll Cardiol. 2003 Dec 3;42(11):1933-40
pubmed: 14662255
J Am Coll Cardiol. 2003 Sep 17;42(6):991-7
pubmed: 13678918
Clin Nutr. 2010 Dec;29(6):745-8
pubmed: 20627486
Cancer. 1989 Jun 1;63(11 Suppl):2298-307
pubmed: 2655867
Am J Cardiol. 2020 Feb 15;125(4):575-582
pubmed: 31843232
N Engl J Med. 1971 Dec 23;285(26):1441-6
pubmed: 5122894
Int J Cardiol. 2019 Apr 1;280:163-175
pubmed: 30661849
Eur J Heart Fail. 2012 Jan;14(1):39-44
pubmed: 22158777
JAMA. 2000 Jun 14;283(22):2941-7
pubmed: 10865271
Am J Med. 2004 Apr 5;116 Suppl 7A:11S-26S
pubmed: 15050883
Cancer Invest. 2005;23(1):84-93
pubmed: 15779871
Circ J. 2015;79(6):1255-62
pubmed: 25912696
N Engl J Med. 1985 Apr 4;312(14):932-6
pubmed: 4038784
Int J Cardiol. 2017 Aug 15;241:387-392
pubmed: 28365180
Heart Vessels. 2019 Dec;34(12):1909-1916
pubmed: 31144097
Am J Med. 2004 Feb 15;116(4):253-62
pubmed: 14969654
J Am Coll Cardiol. 2018 Oct 30;72(18):2231-2264
pubmed: 30153967
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3):656-65
pubmed: 20159360
Am J Cardiol. 1967 Oct;20(4):457-64
pubmed: 6059183
J Cardiol. 2018 Aug;72(2):89-93
pubmed: 29588087
Eur J Oncol Nurs. 2005;9 Suppl 2:S35-8
pubmed: 16437756
J Am Coll Cardiol. 2009 Jun 16;53(24):2231-47
pubmed: 19520246
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Eur Heart J. 2007 Nov;28(22):2706-13
pubmed: 17901079
Lancet. 2001 Aug 4;358(9279):351-5
pubmed: 11502313
Am J Cardiol. 2013 Dec 15;112(12):1867-72
pubmed: 24063839

Auteurs

Masashi Nozaka (M)

Department of Cardiology and Nephrology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.

Hiroaki Yokoyama (H)

Department of Cardiology and Nephrology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.

Kazutaka Kitayama (K)

Department of Cardiology and Nephrology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.

Daiki Nagawa (D)

Department of Cardiology and Nephrology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.

Misato Hamadate (M)

Department of Cardiology and Nephrology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.

Naotake Miura (N)

Department of Cardiology and Nephrology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.

Yosuke Kawamura (Y)

Department of Cardiology and Nephrology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.

Masamichi Nakata (M)

Department of Cardiology and Nephrology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.

Fumie Nishizaki (F)

Department of Cardiology and Nephrology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.

Kenji Hanada (K)

Department of Cardiology and Nephrology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.

Takashi Yokota (T)

Department of Cardiology and Nephrology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.

Masahiro Yamada (M)

Department of Cardiology and Nephrology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.

Hirofumi Tomita (H)

Department of Cardiology and Nephrology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan tomitah@hirosaki-u.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH